Valneva Shares Drop 3.57% Breaking Support at €2.21
On Thursday, the Lyon-based biotech continues its decline while the SBF 120 sees a slight increase. The stock breaks a new technical threshold and is among the biggest losers in the index on the day of its annual general meeting.
Valneva Breaks Support at €2.21 and Slides Among the Biggest Losers of the SBF 120
Valneva's stock falls 3.57% to €2.19 mid-morning, after breaking its support level at €2.21 during the session. The stock is among the biggest losers in the SBF 120, which is up by 0.25%. The session extends a deteriorating trajectory: the biotech is down 11.5% over a month and 22.8% over three months. The decline continues a troubling trend, previously noted at the breach of the €2.26 threshold in early June with the break of a previous technical level. The stock is now significantly below its moving averages: 7.6% from the MM20 (€2.37), 10.3% from the MM50 (€2.44), and nearly 40% from the MM200 (€3.64), confirming the degradation of the medium and long-term trend. The RSI at 43 remains in a neutral zone, indicating that the day's drop has not yet shifted into a clear oversold configuration. The annual general meeting, convened this Thursday, June 25, is by nature a statutory appointment with no market effect in itself. It takes place in a deteriorated stock market environment for the biotech, whose capitalization reflects commercial uncertainty around its travel vaccines.
Lowered 2026 Guidance Continues to Weigh on Trajectory
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The fundamental context sheds light on the underlying decline. During the first quarter of 2026 announcement on May 13, 2026, the company adjusted its revenue forecasts for the year, now targeting between €135 and €150 million. This adjustment reflected particularly unfavorable trends in the adoption of travel vaccines and a decline in third-party product sales, two risks identified in the quarterly report. The management then highlighted a focus on key strategic projects, including LB6V, the Lyme disease candidate developed in partnership with Pfizer, presented at several investor conferences in June. On the stock market front, the break below the €2.21 support further weakens the graphical configuration. Beyond today's general meeting, the next significant financial update expected by the market is the mid-year publication, which will measure the gap between the commercial trajectory and the revised revenue range.
SectorSanté · Vaccins et laboratoires de recherche›Industrie Pharmaceutique
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2025
Guidance from the release
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
